PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.

Continuous processing Downstream processing FDA Facility risk mitigation Health Canada Novel format molecules PEI Regulatory agencies Regulatory perspective Resin lifetime Strategy Submission Upstream processing Viral Clearance Symposium Viral clearance Viral safety

Journal

PDA journal of pharmaceutical science and technology
ISSN: 1948-2124
Titre abrégé: PDA J Pharm Sci Technol
Pays: United States
ID NLM: 9439538

Informations de publication

Date de publication:
Historique:
pubmed: 21 4 2019
medline: 9 4 2020
entrez: 21 4 2019
Statut: ppublish

Résumé

This workshop report summarizes the presentations, the breakout session outcomes, and the speaker panel discussions from the PDA Biosimilars Workshop held September 27-28, 2018, in Washington, DC. This format was deliberately selected for the workshop with the expectation of delivering a post-workshop paper on current best practices and existing challenges for sponsors. The event, co-chaired by Dr. Stephan Krause (AstraZeneca Biologics) and Dr. Emanuela Lacana (CDER/FDA), was attended by 140 agency and industry representatives. The workshop was separated into three major sessions P1: Regulatory Perspective, P2: Challenges in Biosimilar Development, and P3: Demonstrating Analytical Similarity. Each of the three sessions started with agency and industry presentations. Participants then split into two concurrent roundtable discussion groups to hear the answers to questions that had been provided to all participants one week prior to the event. The sessions were recorded. This paper provides consolidated answers to specific case studies for current challenges to sponsors and agencies. In addition, the panel discussion notes following each breakout roundtable session, as well as brief talk summaries of all speakers, are provided. The first session explored the challenges encountered with submission of biosimilar marketing applications from the perspectives of regulatory agencies. Expectations for a successful submission of the chemistry, manufacturing, and controls (CMC) information were described. The second session addressed high-level technical challenges and how to avoid pitfalls frequently encountered during biosimilar candidate development, including data quality expectations, creation of the final control strategy, and strategic choices necessary for candidate selection and development. Both regulatory perspectives and industry experience were shared. The last session explored the use of statistical tools to provide meaningful contributions to the demonstration of analytical similarity. The presentations highlighted common issues and practical challenges that arise during the application of statistical tools.

Identifiants

pubmed: 31004040
pii: pdajpst.2019.010215
doi: 10.5731/pdajpst.2019.010215
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-416

Informations de copyright

© PDA, Inc. 2019.

Auteurs

Stephan Krause (S)

AstraZeneca Biologics, 1 Medimmune Way, Gaithersburg, MD 20878; Stephan.Krause@astrazeneca.com.

Emanuela Lacana (E)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Joel Welch (J)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Marjorie Shapiro (M)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Christopher Downey (C)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Jee Chung (J)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Qing Zhou (Q)

CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993.

Martijn Van Der Plas (M)

Medicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, The Netherlands.

Chantal Depatie (C)

Health Canada, 100 Eglantine Driveway, Ottawa, ON K1A 0K9, Canada.

Bev Ingram (B)

Pfizer Inc., 1 Burtt Road, Andover, MA 01810.

Catherine Srebalus-Barnes (C)

Pfizer Inc., 275 North Field Drive, Lake Forest, IL 60045.

Alla Polozova (A)

Amgen Inc., 360 Binney Street, Cambridge, MA 02142.

Barbara Rellahan (B)

Amgen, Inc., 601 13th Street, NW, Suite 1100 North, Washington, DC 20005.

Daeseok Choi (D)

CELLTRION Inc., 19, Academy-ro 51, Yeonsu-gu, Incheon 406-840, Republic of Korea.

Richard Burdick (R)

Burdick Statistical Consulting, LLC, 7783 Renegade Hill Drive, Colorado Springs, CO 80923.

Thomas Stangler (T)

Novartis, Biochemiestraße 10, 6336 Langkampfen, Austria; and.

Emily Shacter (E)

ThinkFDA, LLC, 710 Erie Ave, Takoma Park, MD 20912.

Articles similaires

1.00
Humans Personnel Staffing and Scheduling Nursing Staff, Hospital Male Adult

Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.

Lisa Larrimore Ouellette, Bhaven N Sampat
1.00
United States Cross-Sectional Studies Patents as Topic Humans Drugs, Generic
Humans Cataract Extraction Virtual Reality Clinical Competence Simulation Training
Humans Pilot Projects Delphi Technique Consensus Congresses as Topic

Classifications MeSH